ClinicalTrials.gg

Program

taragarestrant

Also written as “D-0502” and “[14C]-D-0502”.

Its studies are mostly in Breast Neoplasms, led by InventisBio.

Furthest: phase 3, since Dec 20, 20245 company-led studies, 1 open or runningNext primary completion: Nov 30, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
InventisBio51 open or runningphase 3since Dec 20, 2024Mar 14, 2018Nov 30, 2026phase 3 · NCT06954961

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 14, 2018First study: phase 1 study in Breast NeoplasmsFirst studyNCT03471663 · 200 enrolled · United States, China
  2. Dec 16, 2018Phase 1 study in Breast NeoplasmsNCT03810625 · 14 enrolled · United States
  3. Oct 22, 2021Phase 1 study in Healthy Female VolunteerNCT05226338 · 18 enrolled · United States
  4. Mar 25, 2022Phase 1 study in Mass Balance RecoveryNCT05339633 · 8 enrolled · United States
  5. Dec 20, 2024Phase 3 study in Breast NeoplasmsNCT06954961 · 640 planned · China

Ahead

  1. Nov 30, 2026Primary completion: phase 3 study in Breast NeoplasmsNCT06954961

TargetBeta

ESR1 →read by rule
“An orally available, nonsteroidal selective estrogen receptor degrader/downregulator (SERD), ”NCIt, by rule

Other programs on ESR1

ProgramCompanyFurthest phaseStudies
Ethinyl EstradiolruleJohnson & Johnsonphase 470
EstradiolruleNovo Nordiskphase 469
FulvestrantruleAstraZenecaphase 430
TamoxifenruleAstraZenecaphase 421
ClomipheneruleHamad Medicalphase 43
vepdegestrantrulePfizerphase 320
camizestrantruleAstraZenecaphase 318
giredestrantHoffmann-La Rochephase 317
HRS-8080Jiangsu HengRui Medicinephase 313
elacestrantruleMenarini Groupphase 312
ImlunestrantruleEli Lillyphase 312
SIM0270ruleSimcere Pharmaceutical Groupphase 35

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06954961Breast Neoplasms · China3RecruitingNov 30, 2026640
NCT05339633Mass Balance Recovery · United States1CompletedAug 2, 20228
NCT05226338Healthy Female Volunteer · United States1CompletedDec 23, 202118
NCT03810625Breast Neoplasms · United States1CompletedNov 21, 201814
NCT03471663Breast Neoplasms · United States, China1CompletedOct 18, 2023200

How it is read

Names in the registry

  • “D-0502”, 4 entries
  • “[14C]-D-0502”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.